1-(3-hydroxypropyl)piperidin-4-one | 943974-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3-hydroxypropyl)piperidin-4-one
• 英文别名: 1-(3-hydroxypropyl)-4-piperidone
• CAS: 943974-61-6
• 化学式: C₈H₁₅NO₂
• mdl: MFCD13193148
• 分子量: 157.213
• InChiKey: HRQIDUFZNZJPDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-hydroxypropyl)piperidin-4-one 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 为溶剂， 生成 1-(3-hydroxypropyl)-4-piperidone oxime
  参考文献：
  名称：

  CN115677567

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 3-[(2-methoxycarbonylethyl)(3-hydroxypropyl)amino]propionate 在 盐酸 、 水 、 sodium methylate 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 9.0h， 生成 1-(3-hydroxypropyl)piperidin-4-one
  参考文献：
  名称：

  Synthesis and antihistamine evaluations of novel loratadine analogues

  摘要：

  A series of loratadine analogues containing hydroxyl group and chiral center were synthesized. The effect of the synthesized compounds on the histamine-induced contractions of guinea-pig ileum muscles was studied. In addition, the in vivo asthma-relieving effect of the analogues in the histamine induced asthmatic reaction in guinea-pigs was determined. Most of the compounds exhibited definite H-1 antihistamine activity. The S-enantiomers, compounds 2, 4 and 8, are more potent than the R-enantiomers, compounds 1, 3 and 7. Compound 6 was the most active one among the eight synthesized compounds. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.012

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Sheppard S. George

  公开号：US20070203143A1

  公开（公告）日：2007-08-30

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法被披露。
• 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
  申请人：——

  公开号：US20030105098A1

  公开（公告）日：2003-06-05

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2- [转-（4-氨基环己基）]氨基嘌呤，其在抑制细胞周期依赖性激酶，特别是cdk-2方面具有用途。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：OHTAKE Yasuhiro

  公开号：US20080076760A1

  公开（公告）日：2008-03-27

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明旨在提供一种以公式（1）表示的2,3,4,5-四氢-1H-1,5-苯并二氮平衍生物或其药学上可接受的盐，该化合物可作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药物。
• 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06479487B1

  公开（公告）日：2002-11-12

  The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or R3R4N—R5- wherein R2 is selected from the group consisting of C9-C12 alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4 alkyl, and wherein each C9-C12 alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8 alkyl; R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen; R5 is C1-C8 alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof, with the proviso that when R2 is the group wherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C1-C4 alkyl, or (CH2)m-phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of In addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明提供了公式(I)的新化合物，其中R选自R2、R2NH-或R3R4N-R5-组成的群，其中R2选自C9-C12烷基，Z选自苯基、杂环、环烷基和萘基；M选自氢、C1-C4烷基和其中每个C9-C12烷基或Z可选择地被1-3个取代基取代，这些取代基可以相同也可以不同，选自D、E组成的群，其中每个D独立地选自三氟甲基、三氟甲氧基和C1-C4烷氧基；每个E独立地选自卤素、羟基和C1-C8烷基；R3和R4选自氢、C1-C4烷基和(CH2)y-苯基，其中y是0-8的整数，但R3和R4不能同时为氢；R5是C1-C8烷基；R1选自环戊基、环戊烯基和异丙基，以及其药学上可接受的盐、光学异构体和水合物，但当R2为n为1或更大的基团时；R1为异丙基或环戊基；R6为氢、C1-C4烷基或( )m-苯基；Z为苯基、杂环或环烷基，但Z被1-3个取代基取代，这些取代基可以相同也可以不同，选自此外，本发明提供了一种抑制细胞周期依赖性激酶，特别是cdk-2的方法。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06642231B2

  公开（公告）日：2003-11-04

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2-[trans-(4-氨基环己基)氨基]嘌呤，其对抑制细胞周期依赖性激酶，特别是cdk-2具有用处。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。